VERAXA Biotech AG (NASDAQ: VRXA), a developer of next-generation antibody-based cancer therapies, has announced the appointment of Raju Willener as chief financial officer, effective immediately. Willener brings over three decades of international financial leadership experience, spanning global capital markets, investment banking, corporate finance, asset management, and strategic leadership. He will report directly to CEO and Co-Founder Christoph Antz, Ph.D., and is expected to play a key role in supporting the company's capital strategy, evaluating strategic opportunities, and advancing its proprietary BiTAC(R) technology platform and oncology pipeline.
Willener's appointment comes at a critical time for VERAXA as it seeks to accelerate the development of its innovative antibody-based therapeutics, which include bispecific T cell engagers, bispecific antibody-drug conjugates (ADCs), and other novel formats. The company's pipeline is powered by transformative technologies and guided by rigorous quality-by-design principles, with a focus on rapidly moving its candidates into clinical development and beyond. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology.
Willener's extensive background positions him well to guide VERAXA's financial strategy during this pivotal phase. Prior to joining VERAXA, he served as director of corporate development at Exentis Group AG before being appointed CFO in 2025, where he led mergers and acquisitions initiatives, financial strategy, and key corporate functions. Earlier in his career, he held senior executive and investment positions overseeing corporate finance, capital markets, investor relations, and investment portfolios exceeding CHF 30 billion in assets under management. His experience in managing large-scale financial operations and capital markets will be invaluable as VERAXA seeks to fund its ambitious research and development efforts.
The announcement is significant for the biotech industry, as VERAXA is pushing the boundaries of cancer treatment through its BiTAC(R) platform, which is designed to harness the power of T cells to target and eliminate cancer cells more effectively. The company's focus on bispecific T cell engagers and ADCs represents a growing trend in oncology toward more precise and potent therapies. With a seasoned financial leader at the helm, VERAXA is better positioned to secure the necessary funding to advance its pipeline, potentially bringing new treatment options to patients in need.
For investors, this move signals VERAXA's commitment to strong financial governance and strategic growth. The company's ability to attract a leader of Willener's caliber underscores its potential in the competitive biotech landscape. As VERAXA continues to develop its therapies, the appointment of a CFO with deep capital markets expertise may enhance investor confidence and support future fundraising efforts.
The latest news and updates regarding VERAXA are available in the company's newsroom at nnw.fm/VRXA. To view the full press release, visit https://nnw.fm/jcHOU.
